Skip to content

Released Feb 26, 2024, after the close

10-K filed Feb 26, 2024, 57 days after period end · 0000950170-24-020158

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.68Mderived−96.2% vs Q4 2022−13.8% vs Q3 2023
Net Income-$44.12MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$48,075,000N/M
Operating Cash Flowderived-$36,637,000N/M
Free Cash Flowderived-$36,818,000N/M
Margins · derived
Operating margin-2868.4%−2723.2 pt vs Q4 2022
Net margin-2632.6%−2505.5 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$1.68M$44.36M$17.07M$15.90M
Net Income-$44.12M-$56.36M-$68.62M-$53.11M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR